Cellastra Inc

Cellastra Inc. is a privately-held biotechnology company situated in the San Francisco Financial District. Founded and led by experienced industry professionals, Cellastra employs three individuals and generates approximately $2.5 million in annual revenue. Cellastra specializes in developing innovative gene therapies aimed at addressing critical medical needs. Their focus areas include respiratory infections such as COVID-19 and RSV, women's health, aesthetic surgery, and burn care. The company's proprietary technology involves gene vectors delivering anti-scarring peptides to prevent excessive scarring after surgery and in respiratory infections. Cellastra's gene vector technology, referred to as Cellexa for surgical applications and Virexa for respiratory use, aims to achieve scarless wound healing. This is accomplished by encoding for the continuous production of anti-scarring peptides at the site of injury. Cellastra's research and development efforts are grounded in scientific proof of concept data for their anti-scarring peptide, ensereptide. For further information about Cellastra Inc. and their groundbreaking gene therapies, please visit their website at cellastra.com.